LONDON--(BUSINESS WIRE)--The global bladder cancer therapeutics market is projected to grow to USD 656.6 million by 2021, at a CAGR of nearly 5% over the forecast period, according to Technavio’s latest report.
In this report, Technavio covers the market outlook and growth prospects of the global bladder cancer therapeutics market for 2017-2021. Based on the therapy, the market is divided into intravesical therapy, chemotherapy, and preservation therapy segments.
|The high unmet need for bladder cancer therapeutics and favorable regulatory environment are attracting many small and large firms to the global bladder cancer therapeutics market. The market landscape is expected to change dramatically with the introduction of targeted immunotherapies during the forecast period.|
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Technavio’s research study segments the global bladder cancer therapeutics market into the following regions:
Bladder cancer therapeutics in the Americas
“The Americas is the largest segment of the bladder cancer therapeutics market and occupied more than 45% of overall shares in 2016. The presence of many large vendors who focus on the R&D of targeted therapies for the treatment of bladder cancer is expected to drive the market of the market segment,” says Sapna Jha, a lead analyst at Technavio for oncology research.
For instance, Merck has announced the completion of Phase III trials for KEYTRUDA; an investigational compound indicated for use in bladder cancer. Also, Pfizer has a strategic alliance with Merck to develop its investigational product MSB0010718C (avelumab), an anti-PD-L1 antibody for the treatment of multiple types of cancer.
Bladder cancer therapeutics in EMEA
The bladder cancer therapeutics market in EMEA is likely to grow at a moderate rate during the forecast period, due to the increasing development of infrastructure to support advanced medical equipment for the rapid and accurate diagnosis of individuals with bladder cancer. Also, the recent approval of novel immunotherapeutics in EMEA is likely to foster the market growth. For instance, F. Hoffmann-La Roche launched TECENTRIQ - the first cancer immunotherapy which acts as an inhibitor of PD-L1 for the treatment of urothelial (or transitional cell) carcinoma.
Bladder cancer therapeutics in APAC
APAC is the fastest-growing segment of the bladder cancer therapeutics market, projected to showcase a CAGR of nearly 6% over the forecast period. The growth in the region is likely to be driven by the rising availability of the patient pool due to changing lifestyles, characterized by the high consumption of tobacco.
“Vendors in the market need to focus on infrastructure development and make advanced diagnostic tools widely available to ensure the continued growth of the market. Also, the improving socioeconomic conditions are likely to boost the market growth,” says Sapna.
The top vendors in the global bladder cancer therapeutics market highlighted in the report are:
- Bristol-Myers Squibb
- Eli Lilly
- F. Hoffman-La Roche
Browse Related Reports:
- Global Kaposi Sarcoma Market 2017-2021
- Global Multiple Myeloma Drugs Market 2017-2021
- Global Cancer Monoclonal Antibodies Market 2017-2021
Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like central nervous system, urology devices, and vaccines. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, resellers, and end-users.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.